title: Novel seizure phenotype and sleep disruptions in knock-in mice with hypersensitive alpha 4* nicotinic receptors.
abstract: A leucine to alanine substitution (L9'A) was introduced in the M2 region of the mouse alpha4 neuronal nicotinic acetylcholine receptor (nAChR) subunit. Expressed in Xenopus oocytes, alpha4(L9'A)beta2 nAChRs were > or =30-fold more sensitive than wild type (WT) to both ACh and nicotine. We generated knock-in mice with the L9'A mutation and studied their cellular responses, seizure phenotype, and sleep-wake cycle. Seizure studies on alpha4-mutated animals are relevant to epilepsy research because all known mutations linked to autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) occur in the M2 region of alpha4or beta2 subunits. Thalamic cultures and synaptosomes from L9'A mice were hypersensitive to nicotine-induced ion flux. L9'A mice were approximately 15-fold more sensitive to seizures elicited by nicotine injection than their WT littermates. Seizures in L9'A mice differed qualitatively from those in WT: L9'A seizures started earlier, were prevented by nicotine pretreatment, lacked EEG spike-wave discharges, and consisted of fast repetitive movements. Nicotine-induced seizures in L9'A mice were partial, whereas WT seizures were generalized. When L9'A homozygous mice received a 10 mg/kg nicotine injection, there was temporal and phenomenological separation of mutant and WT-like seizures: an initial seizure approximately 20 s after injection was clonic and showed no EEG changes. A second seizure began 3-4 min after injection, was tonic-clonic, and had EEG spike-wave activity. No spontaneous seizures were detected in L9'A mice during chronic video/EEG recordings, but their sleep-wake cycle was altered. Our findings show that hypersensitive alpha4* nicotinic receptors in mice mediate changes in the sleep-wake cycle and nicotine-induced seizures resembling ADNFLE.
authors.affiliation: Division of Biology, California Institute of Technology, Pasadena, California 91125, USA.
authors.forename: Carlos
authors.initials: C
authors.lastname: Fonck
authors.forename: Bruce N
authors.initials: BN
authors.lastname: Cohen
authors.forename: Raad
authors.initials: R
authors.lastname: Nashmi
authors.forename: Paul
authors.initials: P
authors.lastname: Whiteaker
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Wagenaar
authors.forename: Nivalda
authors.initials: N
authors.lastname: Rodrigues-Pinguet
authors.forename: Purnima
authors.initials: P
authors.lastname: Deshpande
authors.forename: Sheri
authors.initials: S
authors.lastname: McKinney
authors.forename: Steven
authors.initials: S
authors.lastname: Kwoh
authors.forename: Jose
authors.initials: J
authors.lastname: Munoz
authors.forename: Cesar
authors.initials: C
authors.lastname: Labarca
authors.forename: Allan C
authors.initials: AC
authors.lastname: Collins
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Marks
authors.forename: Henry A
authors.initials: HA
authors.lastname: Lester
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation; D018722:Nicotinic Agonists / Q000494:pharmacology / Q000633:toxicity; D010641:Phenotype; D021122:Protein Subunits / Q000096:biosynthesis / Q000235:genetics*; D011978:Receptors, Nicotinic / Q000096:biosynthesis* / Q000235:genetics*; D012640:Seizures / Q000139:chemically induced / Q000235:genetics* / Q000378:metabolism; D012893:Sleep Wake Disorders / Q000235:genetics* / Q000378:metabolism; D014981:Xenopus
chemical_list: D018722:Nicotinic Agonists; D021122:Protein Subunits; D011978:Receptors, Nicotinic; C403531:nicotinic receptor alpha4beta2